Tuberculosis vaccines: Time to reset the paradigm?

Thorax

Volumn 68, Issue 12, 2013, Pages 1092-1094

  Lalvani, Ajit ^a   Sridhar, Saranya ^a   Reyn, C Fordham Von ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; PLACEBO;

ARTICLE; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; MYCOBACTERIUM BOVIS; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; T LYMPHOCYTE; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; MODELS, ANIMAL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 84887416823     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2013-203456     Document Type: Article

References (18)

1. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. Elsevier Ltd; 2013 [cited 28 February 2013];6736:1-8. http://www.ncbi.nlm.nih.gov/ pubmed/23391465
2. Kagina BMN, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 2010 [cited 12 March 2013];182:1073-9. http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid=2970848&tool= pmcentrez&rendertype=abstract
3. Dharmadhikari AS, Nardell EA. What animal models teach humans about tuberculosis. Am J Respir Cell Mol Biol 2008 [cited 25 March 2013];39:503-8. http://www.ncbi.nlm.nih.gov/pubmed/18556589
4. Ernst JD. The immunological life cycle of tuberculosis. Nature Reviews. Immunology Nature Publishing Group; 2012 [cited 29 January 2013];12:581-91. http://www.ncbi.nlm.nih.gov/pubmed/22790178
5. Vordermeier HM, Villarreal-Ramos B, Cockle PJ, et al. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 2009 [cited 26 March 2013];77:3364-73. http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid=2715681&tool= pmcentrez&rendertype=abstract
6. Sharpe SA, McShane H, Dennis MJ, et al. Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing. Clin Vaccine Immunol 2010 [cited 26 March 2013];17:1170-82. http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=2916246&tool=pmcentrez&rendertype= abstract
7. Barker L, Hessel L, Walker B. Rational approach to selection and clinical development of TB vaccine candidates. Tuberculosis (Edinb) Elsevier Ltd; 2012 [cited April 2013];92(Suppl 1):S25-9. http://www. ncbi.nlm.nih.gov/pubmed/ 22441156
8. Soysal A, Millington KA, Bakir M, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005/10/26 ed. 2005;366:1443-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&dopt=Citation&list- uids=16243089 (Pubitemid 41483810)
9. Sridhar S, Pollock K, Lalvani A. Redefining latent tuberculosis. Future Microbiol 2011;6:1021-35. http://www.ncbi.nlm.nih.gov/pubmed/ 21958142
10. Andrews JR, Noubary F, Walensky RP, et al. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis 2012 [cited 28 February 2013];54:784-91. http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid=3284215&tool= pmcentrez&rendertype=abstract
11. Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45
12. Opie EL, Flahiiff EW, Smith H. Protective inoculation against human tuberculosis with heat-killed tubercle bacilli. Am J Hygeine 1939;29:155-64
13. Von Reyn CF, Bakari M, Arbeit RD, et al. New vaccines for the prevention of tuberculosis in human immunodeficiency virus infection. Int J Tuberc Lung Dis 2012 [cited 24 April 2013];16:718-23. http:// www.ncbi.nlm.nih.gov/pubmed/ 22507085
14. Lahey T, Mitchell BK, Arbeit RD, et al. Polyantigenic interferon-? responses are associated with protection from TB among HIV-infected adults with childhood BCG immunization. PLoS ONE 2011 [cited 14 April 2013];6:e22074. http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=3140474&tool= pmcentrez& rendertype=abstract
15. Von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010 [cited 13 March 2013];24:675-85. http://www.ncbi.nlm. nih.gov/pubmed/20118767
16. Buddle BM, Keen D, Thomson A, et al. Protection of cattle from bovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae. Res Vet Sci 1995 [cited 26 March 2013];59:10-6. http://www.ncbi.nlm.nih.gov/pubmed/8525078
17. Reed SG, Coler RN, Dalemans W, et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proceedings of the National Academy of Sciences of the United States of America 17 Feb 2009 [cited 17 May 2013];106:2301-6
18. Lin PL, Dietrich J, Tan E, et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 2012;122:303-14.